222. Primary nephrotic syndrome Clinical trials / Disease details
Clinical trials : 285 / Drugs : 285 - (DrugBank : 108) / Drug target genes : 62 - Drug target pathways : 191
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00001959 (ClinicalTrials.gov) | December 1999 | 18/1/2000 | Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis) | Pirfenidone in Focal Segmental Glomerulosclerosis:Phase II Study | Fibrosis;Focal Glomerulosclerosis;Kidney Failure;Nephrotic Syndrome;Proteinuria | Drug: Pirfenidone | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | NULL | Completed | 18 Years | N/A | All | 21 | Phase 2 | United States |